-
Je něco špatně v tomto záznamu ?
Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line
N. Cernei, O. Zitka, S. Skalickova, J. Gumulec, M. Sztalmachova, MA. Rodrigo, J. Sochor, M. Masarik, V. Adam, J. Hubalek, L. Trnkova, J. Kruseova, T. Eckschlager, R. Kizek,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2006 do Před 1 rokem
ProQuest Central
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
23588590
DOI
10.3892/or.2013.2389
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- metalothionein metabolismus MeSH
- nádorové biomarkery farmakologie fyziologie MeSH
- nádorové buněčné linie MeSH
- nádory prostaty MeSH
- sarkosin farmakologie fyziologie MeSH
- scavengery volných radikálů metabolismus MeSH
- viabilita buněk MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040814
- 003
- CZ-PrNML
- 005
- 20140114110250.0
- 007
- ta
- 008
- 140107s2013 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/or.2013.2389 $2 doi
- 035 __
- $a (PubMed)23588590
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Cernei, Natalia
- 245 10
- $a Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line / $c N. Cernei, O. Zitka, S. Skalickova, J. Gumulec, M. Sztalmachova, MA. Rodrigo, J. Sochor, M. Masarik, V. Adam, J. Hubalek, L. Trnkova, J. Kruseova, T. Eckschlager, R. Kizek,
- 520 9_
- $a Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a scavengery volných radikálů $x metabolismus $7 D016166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metalothionein $x metabolismus $7 D008668
- 650 _2
- $a nádory prostaty $7 D011471
- 650 _2
- $a sarkosin $x farmakologie $x fyziologie $7 D012521
- 650 _2
- $a nádorové biomarkery $x farmakologie $x fyziologie $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zitka, Ondrej $u -
- 700 1_
- $a Skalickova, Sylvie $u -
- 700 1_
- $a Gumulec, Jaromir $u -
- 700 1_
- $a Sztalmachova, Marketa $u -
- 700 1_
- $a Rodrigo, Miguel Angel Merlos $u -
- 700 1_
- $a Sochor, Jiri $u -
- 700 1_
- $a Masarik, Michal $u -
- 700 1_
- $a Adam, Vojtěch $u - $7 xx0064599
- 700 1_
- $a Hubalek, Jaromir $u -
- 700 1_
- $a Trnkova, Libuse $u -
- 700 1_
- $a Kruseova, Jarmila $u -
- 700 1_
- $a Eckschlager, Tomas $u -
- 700 1_
- $a Kizek, Rene $u -
- 773 0_
- $w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 29, č. 6 (2013), s. 2459-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23588590 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140114110955 $b ABA008
- 999 __
- $a ok $b bmc $g 1005210 $s 839326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 29 $c 6 $d 2459-66 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
- LZP __
- $a Pubmed-20140107